Biological
Diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine clinical trials
- studies test it
- 11
- open now
- 0
- in phase 3
- 10
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 10
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
GlaxoSmithKline (6) · Sanofi Pasteur, a Sanofi Company (3) · Canadian Immunization Research Network (1) · MCM Vaccines B.V. (1)
Often tested with
Tested in the same studies.
13-valent pneumococcal vaccine (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Pneumococcal Vaccines (1) · PHiD-CV vaccine (1) · V419 (1) · Heptavalent Pneumococcal Conjugate Vaccine (1)
Studies
Open first, then newest update. How each study uses diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine is read from its arms, and is right about nine times in ten.
Testing it · 11
- Vaccinating Children After ChemotherapyCompletedPhase 4Canadian Immunization Research NetworkNCT02447718Written as Pediacel®
- Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.CompletedPhase 3GlaxoSmithKlineNCT00609492Written as Infanrix™-IPV/Hib
- A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in RussiaCompletedPhase 3GlaxoSmithKlineNCT02858440Written as Infanrix-IPV/Hib
- Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/HibCompletedPhase 3GlaxoSmithKlineNCT00652951Written as Pediacel™
- Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)CompletedPhase 3MCM Vaccines B.V.NCT01839188Written as Pediacel®
- Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ VaccineCompletedPhase 3GlaxoSmithKlineNCT01086423Written as Infanrix-IPV/Hib™
- Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)CompletedPhase 3GlaxoSmithKlineNCT00964028Written as Infanrix™-IPV/Hib
- Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian InfantsWithdrawnPhase 3GlaxoSmithKlineNCT03128489Written as Infanrix-IPV/Hib
- Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00343421Written as PEDIACEL® and Prevenar®
- Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00287092Written as DT5aP-IPV-Hib 5-component Pertussis vaccine
- Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00355654Written as DT5aP-IPV-Hib 5-component Pertussis vaccine
Given in every arm · 5 — diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine is usual care beside what is tested
- Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic TreatmentCompletedPhase 4GlaxoSmithKlineNCT01235949Written as Infanrix-IPV/Hib
- Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in ChildrenTerminatedPhase 2GlaxoSmithKlineNCT01003418Written as Infanrix™-IPV/Hib
- Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster DoseCompletedPhase 3GlaxoSmithKlineNCT01119625Written as Infanrix-IPV/Hib
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of AgeCompletedPhase 3GlaxoSmithKlineNCT00808444Written as Infanrix-IPV/Hib
- Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00384059Written as Pediacel
As the comparator · 3 — what is tested is compared with diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult PopulationsRecruitingPhase 4Sinovac Biotech Co., LtdNCT07354269Written as DTaP-IPV-Hib
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)Active, not recruitingPhase 3CanSino Biologics Inc.NCT05951725Written as DTaP-IPV-Hib
- Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in InfantsCompletedPhase 2GlaxoSmithKlineNCT00871338Written as Pediacel™